• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [15895 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2013 NIHR Health Technology Assessment programme The clinical and cost-effectiveness of rifaximin for maintaining remission from episodes of hepatic encephalopathy
2013 NIHR Health Technology Assessment programme Ranibizumab for the treatment of choroidal neovascularisation associated with pathological myopia
2013 NIHR Health Technology Assessment programme Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2 positive metastatic or locally recurrent unresectable breast cancer: a single technology appraisal
2013 NIHR Health Technology Assessment programme Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis
2013 NIHR Health Technology Assessment programme Lenalidomide for the treatment of myelodysplastic syndromes associated with deletion 5q cytogenetic abnormality
2013 NIHR Health Technology Assessment programme Aflibercept solution for injection for the treatment of wet age-related macular degeneration
2013 NIHR Health Technology Assessment programme Aflibercept in combination with irinotecan and fluorouracil-based therapy for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy
2013 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous coronary intervention for chronic total occlusion]
2013 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Implantation of a lumbar artificial endoprosthesis (anuloplasty/anular repair device)]
2013 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Repair of cartilage defects via matrix-associated autologous chondrocyte immigration]
2013 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous transluminal angioplasty (PTA) of periphery arteries with drug-eluting balloon (DEB)]
2013 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Endovascular repair of aortic aneurysms]
2013 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous transcatheter closure of prosthetic mitral and aortic paravalvular leaks]
2013 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous transluminal septal myocardial ablation (PTSMA) in hypertrophic obstructive cardiomyopathy (HOCM)]
2013 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous transluminal coronary angioplasty (PTCA) with paclitaxel-coated drug-eluting balloon (DEB). Update 2013]
2013 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Duodeno-jejunal bypass liner (DJBL) for patients with obesity, with/without type 2 diabetes mellitus]
2013 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [P16/Ki-67 dual stain in the triage of PAPIII/IIID cytology in cervical cancer screening]
2013 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pomalidomide (Pomalyst®) for the treatment of refractory multiple myeloma or relapsed and refractory multiple myeloma
2013 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Regorafenib (Stivarga®) in pts with metastatic colorectal cancer (CRC) who have progressed after standard therapy
2013 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Mental health rehabilitation for children and adolescents – a literature overview of indications, outcomes and evaluation instruments]
2013 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Zostavax for the prevention of herpes zoster and postherpetic neuralagia. Pilot assessment using the draft HTA core model for rapid relative effectiveness assessment. Pilot-ID: WP-SA-1]
2013 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Identifying ineffective interventions and health technologies: models and their implementation]
2013 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Dabrafenib (Tafinlar®) in previously untreated subjects with BRAF mutation-positive advanced (stage III) or metastatic (stage IV) melanoma
2013 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Occupational therapy in children; Part 1 – Literature review on indications, utilisation and recommendations]
2013 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Evidence requirements for the authorization and reimbursement of high-risk medical devices in the USA, Europe, Australia and Canada: an analysis of seven high-risk medical devices
2013 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Afatinib (Gilotrif®) for first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s)
2013 NIHR Health Technology Assessment programme Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: a systematic review and economic evaluation
2013 NIHR Health Technology Assessment programme Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model
2013 NIHR Health Technology Assessment programme Does short cycle antiretroviral therapy impact on inflammation, immune activation, thrombogenesis and CD4 cell dynamics?
2013 NIHR Health Technology Assessment programme HESTER study: Has electrical sinus translated into effective remodelling?
2013 Institut national d'excellence en sante et en services sociaux (INESSS) [Summary of the exploration of the scientific literature on the effects of prostate cancer screening decision aids for the expert panel of the Collège des médecins du Québec]
2013 Institut national d'excellence en sante et en services sociaux (INESSS) [Traumatic and non-traumatic spinal cord injury: a comparative analysis of the characteristics and organization of rehabilitation care and services in Québec]
2013 Institut national d'excellence en sante et en services sociaux (INESSS) [Use of prolotherapy in the treatment of chronic musculoskeletal conditions]
2013 Institut national d'excellence en sante et en services sociaux (INESSS) [Notice on the reimbursement of proton pump inhibitors]
2013 Institut national d'excellence en sante et en services sociaux (INESSS) [Treatment and follow-up of children with sickle cell disease (SCD)]
2013 Institut national d'excellence en sante et en services sociaux (INESSS) [Systemic hyperbaric oxygen therapy for the treatment of idiopathic sudden sensorineural hearing loss]
2013 Institut national d'excellence en sante et en services sociaux (INESSS) [Overview of dabigatran usage among people insured by the public prescription drug insurance plan]
2013 Institut national d'excellence en sante et en services sociaux (INESSS) [Overview of the drugs used by children and adolescents diagnosed with autism spectrum disorder who are covered by the Public Prescription Drug Insurance Plan]
2013 Institut national d'excellence en sante et en services sociaux (INESSS) [Use of intrathecal pumps for the treatment of chronic non-cancer pain]
2013 Institut national d'excellence en sante et en services sociaux (INESSS) [Sublingual immunotherapy for respiratory allergies]
2013 Institut national d'excellence en sante et en services sociaux (INESSS) [Digital screening mammography. Critical analysis of the article by Chiarelli (2013) and literature review]
2013 Institut national d'excellence en sante et en services sociaux (INESSS) [Current strategies for optimizing the relevance of laboratory test prescription: a review of Canadian and international experiences]
2013 Institut national d'excellence en sante et en services sociaux (INESSS) [Patient-based funding: a literature review of experiences in other countries]
2013 Institut national d'excellence en sante et en services sociaux (INESSS) [Notice regarding field trauma triage criteria]
2013 Institut national d'excellence en sante et en services sociaux (INESSS) [Effectiveness of short term social and psychological interventions: a systematic review]
2013 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) lisdexamfetamine dimesylate (Elvanse®)
2013 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Pazopanib (Votrient®)
2013 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) 5-aminolaevulinic acid (Ameluz®)
2013 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild®)
2013 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Raltegravir (Isentress®)
2013 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tegafur/gimeracil/oteracil (Teysuno®)
2013 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Botulinum toxin type A (Botox®)
2013 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Etanercept (Enbrel®)
2013 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Saxagliptin (Onglyza®)
2013 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Lixisenatide (Lyxumia®)
2013 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Sodium phenylbutyrate (Pheburane®)
2013 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Etravirine (Intelence®)
2013 Andalusian Health Technology Assessment Area (AETSA) [Efficacy and safety of ventricular assist devices]
2013 Andalusian Health Technology Assessment Area (AETSA) [A review of indications for ventricular assist device therapy]
2013 Andalusian Health Technology Assessment Area (AETSA) [Efficacy, safety and efficiency of computed tomographic colonography vs. colonoscopy as colorectal cancer screening test]
2013 Andalusian Health Technology Assessment Area (AETSA) [Efficacy, safety and efficiency of electrical spinal cord stimulation for the treatment of chronic musculoskeletal pain]
2013 NIHR Health Technology Assessment programme Pixantrone monotherapy for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma
2013 NIHR Health Technology Assessment programme Pemetrexed for maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small cell lung cancer
2013 Andalusian Health Technology Assessment Area (AETSA) [Breast cancer ablation with radiofrequency. Systematic review]
2013 Andalusian Health Technology Assessment Area (AETSA) [Effectiveness and safety of MRI 3 tesla versus MRI 1.5 tesla. Systematic Review]
2013 Andalusian Health Technology Assessment Area (AETSA) [Hyperthermic intraperitoneal chemotherapy. Efficacy and safety in the treatment of ovarian cancer peritoneal carcino matosis]
2013 Andalusian Health Technology Assessment Area (AETSA) [Safety and efficacy of therapeutic hypothermia for acute ischemic stroke. Systematic review and Meta-analysis]
2013 Health Quality Ontario (HQO) Transcatheter aortic valve implantation for the treatment of aortic valve stenosis: an evidence update
2013 Health Quality Ontario (HQO) OHTAC recommendation: transcatheter aortic valve implantation for treatment of aortic valve stenosis
2013 Health Quality Ontario (HQO) Photoselective vaporization for the treatment of benign prostatic hyperplasia
2013 Health Quality Ontario (HQO) OHTAC recommendation: photoselective vaporization for the treatment of benign prostatic hyperplasia
2013 Health Quality Ontario (HQO) Optimizing chronic disease management in the community (outpatient) setting (OCDM): an evidentiary framework
2013 Health Quality Ontario (HQO) OHTAC recommendation: optimizing chronic disease management in the community (outpatient) setting (OCDM)
2013 Health Quality Ontario (HQO) Discharge planning in chronic conditions: an evidence-based analysis
2013 Health Quality Ontario (HQO) In-home care for optimizing chronic disease management in the community: an evidence-based analysis
2013 Health Quality Ontario (HQO) Continuity of care to optimize chronic disease management in the community setting: an evidence-based analysis
2013 Health Quality Ontario (HQO) Impact of advanced (open) access scheduling on patients with chronic diseases: an evidence-based analysis
2013 Health Quality Ontario (HQO) Screening and management of depression for adults with chronic diseases: an evidence-based analysis
2013 Health Quality Ontario (HQO) Self-management support interventions for persons with chronic disease: an evidence-based analysis
2013 Health Quality Ontario (HQO) Specialized nursing practice for chronic disease management in the primary-care setting: an evidence-based analysis
2013 Health Quality Ontario (HQO) Electronic tools for health information exchange: an evidence-based analysis
2013 Health Quality Ontario (HQO) Health technologies for the improvement of chronic disease management: a review of the Medical Advisory Secretariat evidence-based analyses between 2006 and 2011
2013 Health Quality Ontario (HQO) Optimizing chronic disease management mega-analysis: economic evaluation
2013 Health Quality Ontario (HQO) How diet challenges are magnified in vulnerable or marginalized people with diabetes and heart disease: a systematic review and qualitative meta-synthesis
2013 Health Quality Ontario (HQO) Chronic disease patients' experiences with accessing health care in rural and remote areas: a systematic review and qualitative meta-synthesis
2013 Health Quality Ontario (HQO) Patient experiences of depression and anxiety with chronic disease: a systematic review and qualitative meta-synthesis
2013 Health Quality Ontario (HQO) Experiences of patient-centredness with specialized community-based care: a systematic review and qualitative meta-synthesis
2013 Health Quality Ontario (HQO) Electrical stimulation for drug-resistant epilepsy: an evidence-based analysis
2013 Health Quality Ontario (HQO) Electrical stimulation for drug-resistant epilepsy: OHTAC recommendation
2013 Health Quality Ontario (HQO) Carbon-13 urea breath test for Helicobacter pylori infection in patients with uninvestigated ulcer-like dyspepsia: an evidence-based analysis
2013 Health Quality Ontario (HQO) Carbon-13 urea breath test for Helicobacter pylori infection in patients with uninvestigated ulcer-like dyspepsia: OHTAC recommendation
2013 Health Quality Ontario (HQO) Cost-effectiveness of the carbon-13 urea breath test for the detection of Helicobacter pylori: an economic analysis
2013 Health Quality Ontario (HQO) Hysteroscopic tubal sterilization: an evidence-based analysis
2013 Health Quality Ontario (HQO) Hysteroscopic tubal sterilization: OHTAC recommendation
2013 Health Quality Ontario (HQO) Hysteroscopic tubal sterilization: a health economic literature review
2013 Health Quality Ontario (HQO) Vitamin B12 and cognitive function: an evidence-based analysis
2013 Health Quality Ontario (HQO) Vitamin B12 and cognitive function: OHTAC recommendation
2013 Health Quality Ontario (HQO) Vitamin B12 intramuscular injections versus oral supplements: a budget impact analysis
2013 Health Quality Ontario (HQO) Deep brain stimulation for treatment-resistant depression: a preliminary evidence review
2013 Health Quality Ontario (HQO) OHTAC recommendation: deep brain stimulation for treatment-resistant depression